Last updated: February 16, 2026
What is NDC 42291-0072?
NDC 42291-0072 corresponds to a specific drug product, classified as a branded or generic pharmaceutical under the National Drug Code (NDC) system. For this product, the label indicates it is a biologic or biosimilar, or a small-molecule drug, although clarification is necessary for precise classification.
(Note: The following analysis assumes NDC 42291-0072 refers to a biosimilar or a branded small-molecule drug, as NDCs are assigned to products in the U.S. market.)
How does the market for this drug currently look?
Market size and dynamics
- The drug market involving NDC 42291-0072 is influenced by therapeutic area, patient population, and competing products.
- Based on recent regulatory approvals, the biosimilar segment has experienced consistent growth, with an annual market expansion rate of approximately 13% over the past five years. The biologic and biosimilar segments collectively reached a market size of $60 billion in 2022 globally, with the U.S. accounting for around 45%.[1]
- The product's therapeutic category could be a significant driver. For example, biosimilars used in oncology or autoimmune diseases benefit from high treatment volumes.
Competitive landscape
- The number of competitors varies; in biosimilars, an average of three to seven concurrent products may target the same reference biologic.
- Patent expirations of key reference biologics have accelerated biosimilar entry, reducing prices and increasing market accessibility.
- For small-molecule drugs, patent cliffs and generic competition influence price points and market share.
Regulatory context
- The drug's approval status impacts market penetration. If already approved by the FDA with a designated interchangeability status, market adoption is faster.
- IP challenges or exclusivity periods will shape initial sales and force price adjustments.
What are recent pricing trends for this class of drugs?
Current list prices
- Biosimilars in the U.S. have list prices approximately 15-30% lower than the reference biologic.
- Small-molecule generics typically see price reductions of 80-90% post-patent expiry.
Reimbursement landscape
- CMS and private payers increasingly prefer biosimilars due to cost savings.
- Many payers implement formulary strategies favoring low-cost biosimilars, influencing reimbursement prices.
Price evolution over time
- Initial launch prices tend to be set around 15-20% below reference biologics or original brand.
- Over the first two years, prices generally decline further as market share shifts and more competitors enter.
What are the price projections for the next five years?
| Year |
Estimated Average Wholesale Price (AWP) |
Notes |
| 2023 |
$X,XXX |
Based on current trend, initial launch pricing. |
| 2024 |
-10% to -20% |
Anticipated market entry of competitors, increased biosimilar approvals. |
| 2025 |
-20% to -30% |
Market saturation with additional biosimilars. |
| 2026 |
-30% to -40% |
Price stabilization at lower levels, driven by payer negotiations. |
| 2027 |
-40% to -50% |
Further erosion in price as multiple alternatives compete. |
(Note: Precise projections require product-specific data, but these ranges reflect typical trends in biosimilar and small-molecule markets.)
How do policy and market forces impact future prices?
- Federal policies encouraging biosimilar uptake, such as the Biologics Price Competition and Innovation Act (BPCIA), will continue to favor price reductions.
- Payer contracts and formulary placements heavily influence effective prices paid.
- Patent litigations and legal disputes can temporarily inflate prices if delays occur in biosimilar market entry.
Key Takeaways
- NDC 42291-0072's market expansion depends on its classification—biosimilar or small-molecule—and regulatory approval status.
- Current prices align with competitive trends—biosimilars and generics offer discounts relative to originators.
- Price projections suggest continuous decline over the next five years, driven by increasing competition and policy support.
- Market dynamics favor rapid price erosion post-market entry, especially for biosimilars, with potential stabilization at lower levels.
- Strategic considerations for investors or stakeholders include monitoring regulatory updates, patent expirations, and payer reimbursement policies.
FAQs
Q1. How do biosimilar prices compare to reference biologics?
Biosimilars typically cost 15-30% less than innovator biologics at launch, with further reductions as market share increases.
Q2. What factors influence the speed of price decline?
The presence of multiple competitors, payer policies, and regulatory approvals accelerate price reductions.
Q3. Will regulatory changes impact pricing?
Yes. Policies promoting biosimilar adoption and potential legislation affecting patent terms or pricing can influence future prices.
Q4. How do patent expirations affect market entry?
Patent expirations open opportunities for biosimilar entrants, increasing competition and pressing prices downward.
Q5. Are reimbursement policies likely to favor certain price points?
Yes. Payers prioritize cost-effective options, often negotiating lower reimbursement rates for biosimilars and generics.
References
[1] IQVIA. "The Global Use of Medicine 2022."
[2] Biosimilars Forum. "Market Trends and Policy Updates," 2022.
[3] Centers for Medicare & Medicaid Services. "Policy on Biosimilars," 2022.
